论文部分内容阅读
目的探讨双歧杆菌三联活菌在小儿抗生素相关性腹泻(AAD)的预防和治疗的临床效果,以指导临床合理使用双歧杆菌三联活菌的治疗效果。方法收集2011年6-9月在医院住院治疗的100例支气管炎和肺炎患儿随机分为预防组(A组)和对照组(B组),每组50例,预防组患儿自开始使用抗菌药物起口服双歧杆菌三联活菌散剂,对照组只使用抗菌药物,出现腹泻后均加用蒙脱石散剂和补液治疗;再将B组随机分为B1组(11例)和B2组(12例),B1组仅加用蒙脱石散剂,B2组蒙脱石散剂加用双歧杆菌三联活菌;比较两组患儿腹泻的发生率、严重程度及腹泻持续时间。结果 A组继发AAD11例,发生率为22.0%,B组继发AAD 23例,发生率为46.0%;A组腹泻持续时间(2.73±1.27)d明显短于B组的(4.08±1.70)d(P=0.025);在AAD的治疗过程中腹泻持续时间B2组少于B1组(P=0.004),差异均有统计学意义。结论双歧杆菌三联活菌能有效预防和治疗抗生素相关性腹泻。
Objective To investigate the clinical efficacy of Bifidobacterium triple viable bacteria in the prevention and treatment of pediatric antibiotic-associated diarrhea (AAD) in order to guide the clinical treatment of viable Bifidobacterium triple viable bacteria. Methods A total of 100 children with bronchitis and pneumonia hospitalized in the hospital from June to September in 2011 were randomly divided into prevention group (group A) and control group (group B), 50 cases in each group. The children in prevention group were started using Antibiotics started oral administration of Bifidobacterium triple viable powder, while the control group only used antimicrobial drugs. After the diarrhea was treated with montmorillonite powder and rehydration treatment, group B was randomly divided into B1 group (11 cases) and B2 group 12 cases). B1 group was only treated with montmorillonite powder, B2 group montmorillonite powder plus Bifidobacterium triple viable bacteria. The incidence, severity and duration of diarrhea in both groups were compared. Results The incidence of secondary AAD in group A was 22.0% in group A and 23% in group B, with a rate of 46.0%. The duration of diarrhea in group A was significantly shorter than that in group B (4.08 ± 1.70) d (P = 0.025). During the course of AAD, the duration of diarrhea in B2 group was less than that in B1 group (P = 0.004), the differences were statistically significant. Conclusion Bifidobacterium triple viable bacteria can effectively prevent and treat antibiotic-associated diarrhea.